세계의 두개내 치료제 전달 시장 : 업계 분석, 규모, 점유율, 성장, 동향, 예측(2031년) - 치료별, 적응증별, 지역별

Intracranial Therapeutic Delivery Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

US $ 4,995 ￦ 6,853,000

Unprintable PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.

US $ 8,495 ￦ 11,655,000

Unprintable PDF & Excel (Multi User License upto 5 users)

PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.

US $ 10,600 ￦ 14,544,000

Printable PDF & Excel (Enterprise License above 5 users)

PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 두개내 치료제 전달 시장 규모는 전례없는 성장을 이루려고 합니다. 이 시장은 2024년에 22억 달러에 달할 것으로 보이고, 향후 10년간 CAGR 9%로 급성장할 전망이며, 2031년에는 40억 달러라는 경이적인 규모에 이를 것으로 예측되고 있습니다. 이 급증은 신경학의 혁신적인 치료에 대한 수요가 증가하고 세계 신경 질환의 유병률이 증가하는 것을 반영합니다.

2021년 세계 재생 의료 시장의 약 6.1%를 차지하는 두개내 치료제 전달은 환자 관리를 변화시키는 최전선에 서 있습니다. 세포, 유전자, 효소의 대체 요법에 중점을 둔 이 분야는 무수한 질병의 치료에 새로운 새벽을 약속하고 기존의 치료법으로는 불충분했던 부분에 희망을 부여합니다.

2018년부터 2023년까지, 특히 세포요법 및 유전자요법의 영역에서 두개내 치료제 전달법의 인기와 효능이 현저하게 상승하였습니다. 이 패러다임 교대는 Bristol Myers Squibb, Gilead Sciences & Company, Xcell Biosciences Inc.와 같은 바이오 의약품 선두의 광범위한 조사와 협력에 의해 지원되며 질병 관리 및 예방에 대한 혁신적인 접근법을 강조합니다. 전략적 인수와 제휴를 통해 이러한 주요 기업들이 우수성을 추구함으로써 업계에 새로운 벤치마크가 탄생하고 있습니다.

본 보고서에서는 세계의 두개내 치료제 전달 시장에 대해 조사했으며, 시장 개요와 함께 치료별, 적응증별, 지역별 동향 및 시장 진출기업의 경쟁 동향 등을 제공합니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 정의 및 세분화
• 시장 역학
• 밸류체인 분석
• Porter's Five Forces 분석
• COVID-19의 영향 분석
• 우크라이나와 러시아의 분쟁의 영향
• 경제 개요
• PESTLE 분석

제3장 세계의 두개내 치료제 전달 시장 전망(2018-2031년)

• 세계의 두개내 치료 딜리버리 시장 전망 : 치료별, 금액(10억 달러)(2018-2031년)
• 세계의 두개내 치료 딜리버리 시장 전망 : 적응증별, 금액(10억 달러)(2018-2031년)
• 세계의 두개내 치료 딜리버리 시장 전망 : 지역별, 금액(10억 달러)(2018-2031년)

제4장 북미의 두개내 치료제 전달 시장 전망(2018-2031년)

제5장 유럽의 두개내 치료제 전달 시장 전망(2018-2031년)

제6장 아시아태평양의 두개내 치료제 전달 시장 전망(2018-2031년)

제7장 라틴아메리카의 두개내 치료제 전달 시장 전망(2018-2031년)

제8장 중동 및 아프리카의 두개내 치료제 전달 시장 전망(2018-2031년)

제9장 경쟁 구도

• 치료법 및 적응증별 히트맵
• 기업의 시장 점유율 분석(2023년)
• 경쟁력 대시보드
• 기업 프로파일
  • Novartis AG
  • BioMarin
  • CORESTEM Inc.
  • Alaunos Therapeutics, Inc.
  • Apic Bio
  • Stemedica Cell Technologies, Inc.
  • Voyager Therapeutics
  • Bayer AG
  • Abeona Therapeutics
  • Spark Therapeutics

제10장 부록

AJY

영문 목차

영문목차

The global intracranial therapeutic delivery market is poised for unprecedented growth. According to a comprehensive market analysis, the sector, valued at US$ 2.2 billion in 2024, is projected to burgeon at a compound annual growth rate (CAGR) of 9% over the next decade, culminating in a staggering US$ 4 billion by 2031. This surge reflects the increasing demand for innovative treatments in neurology and the rising prevalence of neurological disorders worldwide.

Intracranial Therapeutic Delivery: A Pillar of Regenerative Medicine

Accounting for approximately 6.1% of the global regenerative medicine market in 2021, intracranial therapeutic delivery stands at the forefront of transforming patient care. With a significant emphasis on cell, gene, and enzyme replacement therapies, this sector promises a new dawn in the treatment of a myriad of conditions, offering hope where traditional modalities fall short.

A Decade in Review: Triumphs and Innovations

The period from 2018 to 2023 has witnessed a notable ascent in the popularity and efficacy of intracranial therapeutic delivery methods, especially in the realms of cell and gene therapy. This paradigm shift, underpinned by extensive research and collaboration among biopharmaceutical giants such as Bristol Myers Squibb, Gilead Sciences & Company, and Xcell Biosciences Inc., underscores a transformative approach to disease management and prevention. The pursuit of excellence by these key players, through strategic acquisitions and partnerships, is setting new benchmarks in the industry.

Market Drivers: A Confluence of Innovation and Opportunity

The market's trajectory is notably influenced by the burgeoning pipeline of cell, gene, and enzyme replacement therapies, which account for a substantial portion of the pharmaceutical industry's research focus. With over 750 trials and more than 200 investigational new drug applications anticipated by the U.S. FDA, the sector is on the cusp of delivering groundbreaking treatments to patients across the globe.

Moreover, a tangible shift towards regenerative therapies over conventional drug-based treatments is reshaping the landscape. These advancements, coupled with supportive government policies, especially in emerging economies, herald a new era of healthcare possibilities.

Challenges and Constraints: Navigating Through Uncertainties

Despite the optimistic outlook, the market faces hurdles, primarily due to the high costs associated with these advanced therapies. The financial implications for patients and healthcare systems, along with a lack of comprehensive reimbursement policies, present significant challenges. Addressing these concerns is crucial for ensuring the accessibility and sustainability of intracranial therapeutic delivery methods.

Geographical Insights: Key Markets and Emerging Players

• United States: Leading the charge with a 36.4% market share, the U.S. is a hotbed for R&D, bolstered by robust government support and regulatory frameworks.
• Germany: With a quarter share of the European market, Germany's robust healthcare expenditure and thriving biopharmaceutical landscape make it a key player in the sector.
• United Kingdom: The U.K.'s commitment to regenerative medicine and its significant contribution to the European advanced therapeutic medicinal products (ATMP) sector underscore its pivotal role in the market's growth.
• South Korea: Demonstrating rapid progress, South Korea's strategic investments in biopharma and biotech are unlocking new possibilities in intracranial therapeutic delivery.

The Competitive Landscape: Fostering Innovation and Collaboration

The market's future is shaped by strategic collaborations, mergers, and acquisitions among leading firms. Innovations and product launches are critical for maintaining competitive advantage and addressing the evolving needs of patients worldwide. Notable developments, such as ElevateBio's lentiviral vector production platform and the collaboration between Biogen and Ginkgo Bioworks, highlight the industry's commitment to revolutionizing intracranial therapeutic delivery.

Key Companies Profiled

• Novartis AG
• BioMarin
• CORESTEM Inc.
• Alaunos Therapeutics, Inc.
• Apic Bio
• Stemedica Cell Technologies, Inc.
• Voyager Therapeutics
• Bayer AG
• Abeona Therapeutics
• Spark Therapeutics

Segmentation of Intracranial Therapeutic Delivery Industry

Intracranial Therapeutic Delivery Market by Therapy:

• Cell-based Therapy
• Gene Therapy
• Enzyme Replacement Therapy

Intracranial Therapeutic Delivery Market by Indication:

• Spinal Muscular Atrophy (SMA)
• Multiple Sclerosis
• Batten Disease
• Amyotrophic Lateral Sclerosis

Intracranial Therapeutic Delivery Market by Region:

• U.S. Intracranial Therapeutic Delivery Market
• Europe Intracranial Therapeutic Delivery Market
• Rest of the World (ROW) Intracranial Therapeutic Delivery Market

Table of Contents

1. Executive Summary

• 1.1. Global Intracranial Therapeutic Delivery Market Snapshot
• 1.2. Future Projections
• 1.3. Key Market Trends
• 1.4. Regional Snapshot, by Value, 2023
• 1.5. Analyst Recommendations

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Market Opportunities
• 2.3. Value Chain Analysis
• 2.4. Porter's Five Forces Analysis
• 2.5. COVID-19 Impact Analysis
  • 2.5.1. Supply
  • 2.5.2. Demand
• 2.6. Impact of Ukraine-Russia Conflict
• 2.7. Economic Overview
  • 2.7.1. World Economic Projections
• 2.8. PESTLE Analysis

3. Global Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031

• 3.1. Global Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
  • 3.1.1. Key Highlights
    • 3.1.1.1. Cell-based Therapy
    • 3.1.1.2. Gene Therapy
    • 3.1.1.3. Enzyme Replacement Therapy
• 3.2. Global Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 3.2.1. Key Highlights
    • 3.2.1.1. Spinal Muscular Atrophy (SMA)
    • 3.2.1.2. Multiple Sclerosis
    • 3.2.1.3. Batten Disease
    • 3.2.1.4. Amyotrophic Lateral Sclerosis
• 3.3. Global Intracranial Therapeutic Delivery Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
  • 3.3.1. Key Highlights
    • 3.3.1.1. North America
    • 3.3.1.2. Europe
    • 3.3.1.3. Asia Pacific
    • 3.3.1.4. Latin America
    • 3.3.1.5. Middle East & Africa

4. North America Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031

• 4.1. North America Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
  • 4.1.1. Key Highlights
    • 4.1.1.1. Cell-based Therapy
    • 4.1.1.2. Gene Therapy
    • 4.1.1.3. Enzyme Replacement Therapy
• 4.2. North America Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 4.2.1. Key Highlights
    • 4.2.1.1. Spinal Muscular Atrophy (SMA)
    • 4.2.1.2. Multiple Sclerosis
    • 4.2.1.3. Batten Disease
    • 4.2.1.4. Amyotrophic Lateral Sclerosis
• 4.3. North America Intracranial Therapeutic Delivery Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 4.3.1. Key Highlights
    • 4.3.1.1. U.S. Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
    • 4.3.1.2. U.S. Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 4.3.1.3. Canada Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
    • 4.3.1.4. Canada Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
  • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031

• 5.1. Europe Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
  • 5.1.1. Key Highlights
    • 5.1.1.1. Cell-based Therapy
    • 5.1.1.2. Gene Therapy
    • 5.1.1.3. Enzyme Replacement Therapy
• 5.2. Europe Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 5.2.1. Key Highlights
    • 5.2.1.1. Spinal Muscular Atrophy (SMA)
    • 5.2.1.2. Multiple Sclerosis
    • 5.2.1.3. Batten Disease
    • 5.2.1.4. Amyotrophic Lateral Sclerosis
  • 5.2.2. BPS Analysis/Market Attractiveness Analysis
• 5.3. Europe Intracranial Therapeutic Delivery Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 5.3.1. Key Highlights
    • 5.3.1.1. Germany Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
    • 5.3.1.2. Germany Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.3.1.3. U.K. Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
    • 5.3.1.4. U.K. Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.3.1.5. France Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
    • 5.3.1.6. France Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.3.1.7. Italy Intracranial Therapeutic Delivery Market by Therapy, Value (US$Bn), 2018 - 2031
    • 5.3.1.8. Italy Intracranial Therapeutic Delivery Market by Indication, Value (US$Bn), 2018 - 2031
    • 5.3.1.9. Turkey Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
    • 5.3.1.10. Turkey Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.3.1.11. Russia Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
    • 5.3.1.12. Russia Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.3.1.13. Rest of Europe Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
    • 5.3.1.14. Rest of Europe Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
  • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031

• 6.1. Asia Pacific Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
  • 6.1.1. Key Highlights
    • 6.1.1.1. Cell-based Therapy
    • 6.1.1.2. Gene Therapy
    • 6.1.1.3. Enzyme Replacement Therapy
• 6.2. Asia Pacific Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 6.2.1. Key Highlights
    • 6.2.1.1. Spinal Muscular Atrophy (SMA)
    • 6.2.1.2. Multiple Sclerosis
    • 6.2.1.3. Batten Disease
    • 6.2.1.4. Amyotrophic Lateral Sclerosis
  • 6.2.2. Others BPS Analysis/Market Attractiveness Analysis
• 6.3. Asia Pacific Intracranial Therapeutic Delivery Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 6.3.1. Key Highlights
    • 6.3.1.1. China Intracranial Therapeutic Delivery Market by Therapy, Value (US$Bn), 2018 - 2031
    • 6.3.1.2. China Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.3.1.3. Japan Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
    • 6.3.1.4. Japan Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.3.1.5. South Korea Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
    • 6.3.1.6. South Korea Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.3.1.7. India Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
    • 6.3.1.8. India Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.3.1.9. Southeast Asia Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
    • 6.3.1.10. Southeast Asia Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.3.1.11. Rest of Asia Pacific Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
    • 6.3.1.12. Rest of Asia Pacific Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
  • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031

• 7.1. Latin America Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
  • 7.1.1. Key Highlights
    • 7.1.1.1. Cell-based Therapy
    • 7.1.1.2. Gene Therapy
    • 7.1.1.3. Enzyme Replacement Therapy
• 7.2. Latin America Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 7.2.1. Key Highlights
    • 7.2.1.1. Spinal Muscular Atrophy (SMA)
    • 7.2.1.2. Multiple Sclerosis
    • 7.2.1.3. Batten Disease
    • 7.2.1.4. Amyotrophic Lateral Sclerosis
  • 7.2.2. BPS Analysis/Market Attractiveness Analysis
• 7.3. Latin America Intracranial Therapeutic Delivery Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 7.3.1. Key Highlights
    • 7.3.1.1. Brazil Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
    • 7.3.1.2. Brazil Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 7.3.1.3. Mexico Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
    • 7.3.1.4. Mexico Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 7.3.1.5. Argentina Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
    • 7.3.1.6. Argentina Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 7.3.1.7. Rest of Latin America Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
    • 7.3.1.8. Rest of Latin America Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
  • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031

• 8.1. Middle East & Africa Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
  • 8.1.1. Key Highlights
    • 8.1.1.1. Cell-based Therapy
    • 8.1.1.2. Gene Therapy
    • 8.1.1.3. Enzyme Replacement Therapy
• 8.2. Middle East & Africa Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 8.2.1. Key Highlights
    • 8.2.1.1. Spinal Muscular Atrophy (SMA)
    • 8.2.1.2. Multiple Sclerosis
    • 8.2.1.3. Batten Disease
    • 8.2.1.4. Amyotrophic Lateral Sclerosis
  • 8.2.2. BPS Analysis/Market Attractiveness Analysis
• 8.3. Middle East & Africa Intracranial Therapeutic Delivery Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 8.3.1. Key Highlights
    • 8.3.1.1. GCC Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
    • 8.3.1.2. GCC Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.3.1.3. South Africa Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
    • 8.3.1.4. South Africa Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.3.1.5. Egypt Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
    • 8.3.1.6. Egypt Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.3.1.7. Nigeria Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
    • 8.3.1.8. Nigeria Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.3.1.9. Rest of Middle East & Africa Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
    • 8.3.1.10. Rest of Middle East & Africa Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
  • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

• 9.1. Therapy vs by Indication Heatmap
• 9.2. Company Market Share Analysis, 2023
• 9.3. Competitive Dashboard
• 9.4. Company Profiles
  • 9.4.1. Novartis AG
    • 9.4.1.1. Company Overview
    • 9.4.1.2. Product Portfolio
    • 9.4.1.3. Financial Overview
    • 9.4.1.4. Business Strategies and Development
  • 9.4.2. BioMarin
    • 9.4.2.1. Company Overview
    • 9.4.2.2. Product Portfolio
    • 9.4.2.3. Financial Overview
    • 9.4.2.4. Business Strategies and Development
  • 9.4.3. CORESTEM Inc.
    • 9.4.3.1. Company Overview
    • 9.4.3.2. Product Portfolio
    • 9.4.3.3. Financial Overview
    • 9.4.3.4. Business Strategies and Development
  • 9.4.4. Alaunos Therapeutics, Inc.
    • 9.4.4.1. Company Overview
    • 9.4.4.2. Product Portfolio
    • 9.4.4.3. Financial Overview
    • 9.4.4.4. Business Strategies and Development
  • 9.4.5. Apic Bio
    • 9.4.5.1. Company Overview
    • 9.4.5.2. Product Portfolio
    • 9.4.5.3. Financial Overview
    • 9.4.5.4. Business Strategies and Development
  • 9.4.6. Stemedica Cell Technologies, Inc.
    • 9.4.6.1. Company Overview
    • 9.4.6.2. Product Portfolio
    • 9.4.6.3. Financial Overview
    • 9.4.6.4. Business Strategies and Development
  • 9.4.7. Voyager Therapeutics
    • 9.4.7.1. Company Overview
    • 9.4.7.2. Product Portfolio
    • 9.4.7.3. Financial Overview
    • 9.4.7.4. Business Strategies and Development
  • 9.4.8. Bayer AG
    • 9.4.8.1. Company Overview
    • 9.4.8.2. Product Portfolio
    • 9.4.8.3. Financial Overview
    • 9.4.8.4. Business Strategies and Development
  • 9.4.9. Abeona Therapeutics
    • 9.4.9.1. Company Overview
    • 9.4.9.2. Product Portfolio
    • 9.4.9.3. Financial Overview
    • 9.4.9.4. Business Strategies and Development
  • 9.4.10. Spark Therapeutics
    • 9.4.10.1. Company Overview
    • 9.4.10.2. Product Portfolio
    • 9.4.10.3. Financial Overview
    • 9.4.10.4. Business Strategies and Development

10. Appendix

• 10.1. Research Methodology
• 10.2. Report Assumptions
• 10.3. Acronyms and Abbreviations

List of Region/Countries

• North America
  • U.S.
  • Canada

• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Turkey
  • Russia
  • Rest of Europe

• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Southeast Asia
  • Rest of Asia Pacific

• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America

• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

관련자료